Shots:

• Vivoryon to receive an up front and is eligible to receive ~$565M upon achievement of development & commercial milestones along with royalties on sales
• Simcere to get a regional license to develop and commercialize varoglutamstat (PQ912) and PBD-C06 in Greater China. The company acquired an option to advance PBD-C06 in the clinical program
• The clinical development program in Greater China is planned to be complementary to Vivoryon's efforts in the EU and the US including the P-IIa VIVIAD trial in the EU & P-IIa/b study in the US which is expected to be initiated in H2’21

  | Ref: Vivoryon | Image: Vivoryon